Raleigh-based Merz North America, a pharmaceutical company specializing in aesthetics, skin care and neurotoxins, wants women to be guilt free about using the company’s anti-wrinkle injection, Xeomin, to smooth frown lines.
Read More
Chapel Hill-based TARGET PharmaSolutions, a clinical data company focused on real-world evidence in disease studies, has formed a strategic partnership with Gilead Sciences to better understand two major liver disorders. Gilead is the sixth major pharmaceutical partner to join in TARGET-NASH, a study of nonalcoholic fatty liver disease, or nonalcoholic...
Read More
URO-1, a medical device startup company in Winston-Salem, has received approval from the U.S. Food and Drug Administration to begin marketing its treatment for an overactive bladder.
Read More
A man suffering from a rare genetic disease has been treated with a novel genome-editing therapy at the University of North Carolina’s Clinical and Translational Research Center.
Read MoreG1 Therapeutics reports positive top-line data from a Phase 2a trial of its potential therapy for patients who are taking chemotherapy for small-cell lung cancer.
Read More
Bioventus, a global orthobiologics company based in Durham, has launched Durolane, its single-injection joint lubricant for treating knee osteoarthritis pain.
Read More
Bob Rhatigan once helped make Botox a huge success for Allergan. Now he’s looking to repeat that performance at Merz NA, which is based in Raleigh. And his decision to hire Christie Brinkley is helping deliver growth. Here’s the backstory about Rhatigan, his decision, family and career.
Read More
LabCorp CEO and Chairman David King talks about his rise to the top of the life science giant’s executive suite, striving to keep his ego under control, challenges of the job, the unfinished business of the company, and the commitment to its hometown. Oh, there’s also the debate about how to pronounce the company’s name.
Read More
Five “alumni” companies of the Council for Entrepreneurial Development reported major progress at the CED’s Life Sciences Conference.
Read More
